Vazyme Biotech Co., Ltd (SHA: 688105), based in China, has entered into a strategic partnership with Shanghai Yufang Medical Technology (Group) Co., Ltd to enhance their collaboration in the screening and testing sector.
Under the terms of the agreement, the two companies will leverage their respective strengths to jointly promote Vazyme’s blood testing products for Alzheimer’s disease (AD). Vazyme will grant Yufang Medical exclusive rights to sell its AD early screening products across major online platforms, including AliHealth, Baidu Health, Taobao, Tmall, Pinduoduo, Meituan, and TikTok, while providing competitive pricing. Yufang Medical will initiate a trial operation based on mutually agreed sales and procurement prices. Following the trial period, both parties will work together to establish a market-aligned pricing system and tiered incentive policies.- Flcube.com
